Q2 FY2026 · ended Jun 30, 2026 · Revenue $450,000 · Filed Sep 2, 2026
Attovia Therapeutics, Inc. (ATTO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $450,000 and a net loss of $20.7 million. Free cash flow was -$35.3 million. As of Jun 30, 2026 it held $115.1 million in cash and investments and $4.3 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATTO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2058707
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $450,000 |
| Operating income | -$21.8M |
| Net income | -$20.7M |
| Diluted EPS | -$4.88 |
| Operating cash flow | -$34.9M |
| Free cash flow | -$35.3M |
| Total assets | $128.3M |
| Total liabilities | $15.6M |
| Stockholders' equity | -$145.5M |
| Cash and investments | $115.1M |
| Total debt | $4.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 6, 2026 | Aug 6, 2026 |
All 56 Attovia Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.